Trials / Completed
CompletedNCT03471897
Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 237 (actual)
- Sponsor
- Chalmers University of Technology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
In this study, the investigators profiled plasma glycosaminoglycans (GAGs) in a retrospective consecutive series of patients with a radiographic finding of renal mass referred to primary surgery for renal cell carcinoma (RCC). A control group was formed by measuring plasma GAGs in healthy volunteers. The primary endpoints were the specificity and sensitivity of plasma GAGs in the detection of early stage RCC in pre-surgical samples versus healthy individuals. The investigators further analyzed how plasma GAGs varied according to stage, grade, RCC histology, other renal masses, and after surgery. Finally, the investigators estimated whether plasma GAGs could be used for prediction and surveillance of RCC recurrence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Glycosaminoglycan plasma score | A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC. |
Timeline
- Start date
- 2016-04-28
- Primary completion
- 2017-10-25
- Completion
- 2018-01-18
- First posted
- 2018-03-21
- Last updated
- 2018-04-17
Source: ClinicalTrials.gov record NCT03471897. Inclusion in this directory is not an endorsement.